Attovia Therapeutics, Inc.: venBio Global Strategic Fund IV, L.P. discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
venBio Global Strategic Fund IV, L.P. disclosed a stake exceeding 5% in Attovia Therapeutics, Inc. via a Schedule 13G filing with the SEC (accession 0000905148-26-004977). The filing signals that venBio has crossed the 5% beneficial ownership threshold, making it a reportable large holder in the company. The exact number of shares and percentage were not specified in the headline disclosure. Investors will watch for further detail in the full filing, including the precise share count and any indication of passive versus active intent.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Attovia Therapeutics, Inc., venBio Global Strategic Fund IV, L.P.